Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

CHMP Adopts Positive Opinion On ADASUVE - Quick Facts

RELATED NEWS
Trade ALXA now with 

Alexza Pharmaceuticals, Inc. (ALXA: Quote) and Grupo Ferrer Internacional, S.A., announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency adopted a positive opinion recommending that ADASUVE be granted European Union centralized marketing authorization.

The CHMP recommends ADASUVE be authorized in the EU for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.

The CHMP positive opinion will now be forwarded to the European Commission. The company expects a decision from the European Commission in the first quarter of 2013.

Alexza filed the ADASUVE Marketing Authorization Application with the European Medicines Agency in October 2011.

Click here to receive FREE breaking news email alerts for Alexza Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The Bank of Japan expanded its massive quantitative and qualitative easing unexpectedly as policymakers assessed it necessary to achieve the 2 percent inflation target even after a sales tax hike in April. In a 5-4 vote, the Policy Board led by Governor Haruhiko Kuroda decided to raise the monetary base at an annual pace of about JPY 80 trillion. LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that its third quarter loss widened slightly from last year, as higher costs and expenses more than offset a 45% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. After ending the previous session modestly lower, stocks moved mostly higher over the course of the trading day on Thursday. The gains on the day more than offset yesterday's losses, lifting the major averages to their best closing levels in a month.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.